Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
|||
| Line 20: | Line 20: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-CCR4 antibodies]] | [[Category:Anti-CCR4 antibodies]] | ||
[[Category:Anti-CD194 antibodies]] | [[Category:Anti-CD194 antibodies]] | ||
Revision as of 19:34, 27 February 2020
Mechanism of action
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. [1][2][3]
Diseases for which it is used
History of changes in FDA indication
- 8/8/2018: Initial approval for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Also known as
- Code name: KW-0761
- Generic name: mogamulizumab-kpkc
- Brand name: Poteligeo